Even as Eli Lilly gets underway with its next major obesity launch in Foundayo, an FDA document related to the oral treatment ...
The U.S. Food and Drug Administration said Eli Lilly is required to conduct post-marketing trials to gauge risks for ...
April 14 (Reuters) - The U.S. Food and Drug Administration has asked Eli Lilly for more data on liver injury linked to its ...
The Medicines and Healthcare products Regulatory Agency (MHRA) on Tuesday approved Novo Nordisk's (NVO) new single-dose 7.2mg ...
Obesity threatens the health of men and women in different ways: the former are more likely to suffer from the accumulation of visceral fat and liver disorders, the latter from inflammation and high ...
Kailera Therapeutics is advancing a pipeline of obesity drugs, led by the GLP-1/GIP dual agonist ribupatide, which the ...
New findings reveal that obesity significantly impaired the quality and longevity of antibody responses to a Pseudomonas aeruginosa vaccine in a mouse model. The impaired antibody production was due ...
A hormone that can reverse obesity in mice is offering new clues about how the brain controls body weight. Researchers at the ...
Eli Lilly and Company (NYSE:LLY | LLY Price Prediction) and Novo Nordisk A/S (NYSE:NVO) reported quarterly results in early ...
MedPage Today on MSN
Proposed Obesity Criteria Could Delay Care, Top Society Warns
Revised diagnostic framework may limit access to early treatment, widen healthcare dispari ...
Guidance from three obesity associations offers recommendations for specific obesity medications and spells out the need to reduce stigma. Will it help?
Kailera is taking another step into the competitive obesity market by aiming to raise up to $528.5 million via a Nasdaq IPO, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results